Mode
Text Size
Log in / Sign up
Phase 4 Completed N=66 Randomized Treatment

Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery

Pain, Postoperative · pelvic organ prolapse
Source: ClinicalTrials.gov NCT03052816 ↗
Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcomePrimary: Visual Analog Scores (VAS) — 20; 40 mm
◆ Published Evidence
Established
45citations · ~6 / year
Multimodal opioid-sparing postoperative pain regimen compared with the standard postoperative pain regimen in vaginal pelvic reconstructive surgery: a multicenter randomized controlled trial.
American journal of obstetrics and gynecology · 2019 · Likely link

Summary

The purpose of this randomized controlled trial is to determine whether, "ICE-T," a novel multimodal postoperative pain regimen composed of around the clock ice packs, toradol, and tylenol, has improved pain control intake compared to the standard postoperative pain regimen in patients undergoing vaginal pelvic floor reconstructive surgery.

Linked Publications

  • Multimodal opioid-sparing postoperative pain regimen compared with the standard postoperative pain regimen in vaginal pelvic reconstructive surgery: a multicenter randomized controlled trial.
    American journal of obstetrics and gynecology · 2019 · 45 citations · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analog Scores (VAS)
20; 40
SECONDARY
VAS Scores at 4 Hours Post Surgery
35; 50
SECONDARY
VAS Scores 96 Hours After Surgery
20; 30
SECONDARY
Quality of Recovery Scores on Post op Day 1
182; 173
SECONDARY
Satisfaction Scores in the Morning After Surgery (7AM)
10; 10
SECONDARY
Satisfaction Scores 96 Hours After Surgery
10; 9
SECONDARY
Length of Stay
24.1; 24.1
SECONDARY
Total Dose of Opioids Administered During Hospitalization
55.7; 91.2
SECONDARY
Postoperative Nausea and Vomiting at 7AM After Surgery
14; 18
SECONDARY
Number of Participants With Urinary Retention.
5; 7

Eligibility Criteria

Inclusion Criteria

  • The inclusion criteria are the following:
  • Consenting, English speaking women between ages 18 and 80 who will undergo same day vaginal female pelvic reconstructive surgery at MetroHealth Medical Center
  • Ability to read VAS Scores
  • Specific vaginal procedures include, but are not limited to:
  • Periurethral bulking
  • Perineoplasty
  • Complete vaginectomy
  • Le Forte colpocleisis
  • Anterior repair
  • Posterior repair
  • Enterocele repair
  • Anterior and posterior repair
  • Anterior, posterior and enterocele repair
  • Transvaginal mesh use
  • Sacrospinous ligament fixation
  • Uterosacral ligament suspension
  • Vaginal paravaginal defect repair
  • Midurethral Sling
  • Sphincteroplasty
  • Vaginal hysterectomy, for uterus 250 g or less
  • Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s)
  • Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s), with repair of enterocele
  • Vaginal hysterectomy, for uterus 250 g or less; with repair of enterocele
  • Vaginal hysterectomy, for uterus greater than 250 g
  • Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)
  • Vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s), with repair of enterocele
  • Vaginal hysterectomy, for uterus greater than 250 g; with repair of enterocele

Exclusion Criteria

  • The exclusion criteria are the following:
  • History of chronic pelvic pain
  • Abdominal surgery
  • Laparoscopic surgery
  • History of psychiatric disease
  • Currently taking analgesic medications
  • Currently taking sedatives
  • Liver disease
  • Renal disease with CrCl < 60cc/min.
  • History of burns from application of ice.
  • Women who did not consent for the study.
  • Intraoperative concern for increased blood loss
  • Unable to speak English
  • Unable to understand VAS Scores
  • Undergoing concomitant abdominal or laparoscopic procedures.
  • Allergy to motrin, toradol, Percocet, Tylenol
  • Active or history of peptic ulcer disease
  • History of GI bleeding or perforation
  • Hemorrhagic diathesis
  • Severe uncontrolled heart failure
  • Inflammatory bowel disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03052816) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search